Md. Code Ann., Health Occ. § 12-6A-01
Definitions
Effective Oct 1, 2023Added by Acts 2002, c. 249, § 1, eff. Oct. 1, 2002. Amended by Acts 2009, c. 314, § 1, eff. Oct. 1, 2009; Acts 2009, c. 315, § 1, eff. Oct. 1, 2009; Acts 2012, c. 658, § 1, eff. July 1, 2012; Acts 2015, c. 269, § 1, eff. Oct. 1, 2015; Acts 2023, c. 399, § 1, eff. Oct. 1, 2023.State of Maryland
- (a) In this subtitle the following words have the meanings indicated.
- (b) “Authorized prescriber” means a licensed physician, licensed podiatrist, or certified advanced practice nurse with prescriptive authority under § 8-508 of this article.
- (c) “Group model health maintenance organization” has the meaning stated in § 19-713.6 of the Health--General Article.
- (d) “Health maintenance organization” has the meaning stated in § 19-701(g) of the Health--General Article.
(e)
- (1) “Institutional facility” means a facility other than a nursing home whose primary purpose is to provide a physical environment for patients to obtain inpatient or emergency care.
- (2) “Institutional facility” does not include an urgent care facility that is not part of a facility.
- (f) “Prescriber-pharmacist agreement” means an agreement between an authorized prescriber and a licensed pharmacist that is disease-state specific and specifies the protocols that may be used.
- (g) “Protocol” means a course of treatment predetermined by the authorized prescriber and licensed pharmacist according to generally accepted medical practice for the proper completion of a particular therapeutic or diagnostic intervention.
(h) “Therapy management contract” means a voluntary arrangement that is:
- (1) Disease-state specific;
(2) Agreed on by:
- (i) One licensed pharmacist and the licensed pharmacist's designated alternate licensed pharmacists;
- (ii) One authorized prescriber and alternate designated authorized prescribers involved directly in patient care; and
- (iii) One patient receiving care from an authorized prescriber and a licensed pharmacist pursuant to a prescriber-pharmacist agreement and protocol under this subtitle; and
- (3) Related to treatment using drug therapy, laboratory tests, or medical devices, under defined conditions or limitations for the purpose of improving patient outcomes.
Added by Acts 2002, c. 249, § 1, eff. Oct. 1, 2002. Amended by Acts 2009, c. 314, § 1, eff. Oct. 1, 2009; Acts 2009, c. 315, § 1, eff. Oct. 1, 2009; Acts 2012, c. 658, § 1, eff. July 1, 2012; Acts 2015, c. 269, § 1, eff. Oct. 1, 2015; Acts 2023, c. 399, § 1, eff. Oct. 1, 2023.